Kardigan Reports $661M Cash, Advances Three Late-Stage Heart Programs
KARD is trading near its 52-week low of $19.58 (4.2% above the low).
Summary
Kardigan reported Q2 2026 results with a strong cash position of $660.7 million following its upsized IPO, funding operations through multiple data readouts. R&D expenses rose to $56.4 million, reflecting increased clinical trial activity across three late-stage cardiovascular programs. The company initiated Phase 3 enrollment for danicamtiv in genetic DCM and randomized the first patient in the Phase 2b KARDINAL-ASH trial for tonlamarsen. Upcoming ESC 2026 presentations in late August will feature new data on danicamtiv and tonlamarsen. Multiple Phase 2b topline readouts are expected in the first half of 2027, marking a catalyst-rich period for the stock.
At the time of this announcement, KARD was trading at $20.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $19.58 to $27.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.